ReviewVaccines2022
Influenza Vaccination Assessment according to a Value-Based Health Care Approach.
Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- A study of booster dose influenza vaccination responses compared to standard dose in lupus patients: an open-labeled, randomized controlled study.Clinical and experimental medicine · 2025Trial
- The impact of influenza vaccination on the clinical severity of influenza among children aged 6 months to 6 years living in the community: a prospective cohort study.Clinical and experimental vaccine research · 2026Article
- Global, regional, and national burden of influenza-associated lower respiratory infections, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.BMC infectious diseases · 2026Article
- Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy.ClinicoEconomics and outcomes research : CEOR · 2026Article
- Chronic Diseases and Influenza Vaccines.Vaccines · 2025Review
- Seasonality of Influenza and Optimizing Timing of Vaccination: Systematic Review and Meta-Analysis.Cureus · 2025Review
- Addressing influenza in Bangladesh: closing evidence and policy gaps with strategic interventions.The Lancet regional health. Southeast Asia · 2025Review
- Health Technology Assessment of Vaccines in Italy: History and Review of Applications.Vaccines · 2024Article
- Article
- The economic and fiscal impact of incremental use of cell-based quadrivalent influenza vaccine for the prevention of seasonal influenza among healthcare workers in Italy.Health research policy and systems · 2024Article
- Review
- What Type of Person Should I Be? About the Appeal to Virtues in Public Health Interventions.Vaccines · 2023Review
- The application of metagenomic next-generation sequencing in pathogen diagnosis: a bibliometric analysis based on Web of Science.Frontiers in cellular and infection microbiology · 2023Review
- Influenza vaccination from the perspective of health care workers at university hospitals.PloS one · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeasonal influenza has a considerable public health impact, and vaccination is the key to preventing its consequences. Our aim was to describe how the value of influenza vaccination is addressed in the scientific literature considering a new value framework based on four pillars (personal, allocative, technical, and societal value).
methodsA systematic review was conducted by querying three databases. The analysis was performed on international studies focused on influenza vaccination value, and the four value pillars were taken into consideration for their description.
resultsOverall, 40 studies were considered. Most of them focused on influenza vaccination in the general population (27.5%), emphasizing its value for all age groups. Most studies addressed technical value (70.4%), especially in terms of economic models and cost drivers to be considered for the economic evaluations of influenza vaccines, and societal value (63%), whereas few dealt with personal (37%) and allocative values (22.2%).
conclusionsThe whole value of influenza vaccination is still not completely recognized. Knowledge and communication of the whole value of influenza vaccination is essential to guide value-based health policies. To achieve this goal, it is necessary to implement initiatives that involve all relevant stakeholders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.